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Disease free survival (DFS) is a surrogate for Overall Survival (OS) in Localized 
Prostate Cancer (CaP) 
Background: Advances in the treatment of localized CaP have lead to decreased recurrences 
and improved OS. The Intermediate Clinical Endpoints in CaP (ICECaP) Working Group is 
conducting an individual patient data (IPD) meta-analysis of possible surrogate endpoints for 
for localized CaP trials.  We hypothesized that DFS is a surrogate for OS.  
Methods: By June 2013, we systematically identified 102 eligible randomized trials (completed 
or ongoing) comparing treatments in localized CaP and collected IPD from trialists. DFS was 
defined from randomization (R) to the first evidence of clinical recurrence (loco-regional or 
distant) or death from any cause; or was censored at the date of last follow-up. OS was defined 
from R to death from any cause. We evaluated the surrogacy of DFS with OS using a meta-
analytic 2-stage validation model where 2 conditions must hold to claim DFS is a surrogate for 
OS (Buyse et al, 2000 & 2011 - table). The secondary objective evaluated surrogacy of time to 
disease recurrence (TDR) with disease specific survival (DSS), defined analogously to DFS and 
OS but with non-CaP deaths censored. 
Results: By January 2016, IPD from 16,999 men randomized in 20 mature trials were available 
for analysis. 32% of the men were from prostatectomy trials, about 30% of the men had 
intermediate and 50% high-risk disease and 86% were <74 yo.  With median follow-up of 10.2 
years, 32% (N=5,370) men had died and 30% of these deaths (N=1,592) were due to CaP. 
Meta-analytic 2-
stage validation 
Model 
Condition 1: 
Correlation between the ICE 
and true endpoint  
Condition 2: 
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study specific 
treatment effect on 
endpoints 
  R2 from weighted 
linear regression of t-
year Kaplan Meier 
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linear regression of 
treatment effects (log 
HR - 95% CI) 
DFS as a surrogate 
for OS 
10y OS vs 5y DFS 
0.80 (0.67,0.86) 
8y OS vs 5y DFS 
0.85 (0.76,0.90) 
0.85(0.85,0.86) 0.80(0.60,0.87) 
TDR as surrogate 
for DSS 
10y DSS vs 5y TDR 
0.73 (0.56,0.81) 
8y DSS vs 5y TDR 
0.79 (0.67,0.85) 
0.71(0.70,0.72) 0.61(0.29,0.75) 
 
Conclusion: DFS is a valid surrogate of OS and the correlation between TDR and DSS supports 
the notion that the correlation is driven by CaP events. 
